CClinicalTrials.gg
RecruitingNCT06391086Updated Apr 13, 2026

Neuromodulation Effect of Focused Ultrasound for Motor Recovery in Patients With Stroke

An interventional study of NaviFUS® Neuronavigation-guided focused ultrasound system and NaviFUS® Neuronavigation-guided focused ultrasound system in Focused Ultrasound and Stroke, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Transcranial focused ultrasound (tFUS) can be used as a non-invasive brain neuromodulation technique. Low-intensity focused ultrasound has been demonstrated to be safe and have neuromodulatory effects on the cerebral cortex in healthy human and animal experiments.This study aims to investigate the effect of tFUS on cortical excitability for motor recovery in patients with stroke.

Read the detailed description

The study is a pilot study for feasibility, which aims to recruit 20 patients with subacute (within 3 months) stroke and unilateral hemiparesis. tFUS stimulation will be delivered to the primary motor cortex on the healthy side. The treatment protocol consists of once daily treatment for consecutive five tFUS sessions. The primary outcomes are defined as cortical excitability assessment in bilateral primary motor cortex, as well as safety analysis; the secondary outcome measures include the Fugl-Meyer Assessment, Medical Research Council score, National Institutes of Health Stroke Scale (NIHSS), Barthel Index, Modified Rankin Scale and functional brain activities. The evaluation will be conducted before treatment and on the first day, first week, fourth week, and twelfth week after completing tFUS.

The second part of this study is an efficacy investigation, which plans to recruit 30 subacute stroke patients for a randomized controlled trial with a parallel-group design. The experimental group will receive focused ultrasound stimulation with the same parameters and target site as the Phase I pilot study, while the control group will receive sham stimulation at the same location. The treatment frequency will be the same as that of the pilot study.

02

Conditions studied

  • Focused Ultrasound
  • Stroke

Browse trials for

03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 50 is close to the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with stroke (including hemorrhagic or ischemic stroke) diagnosed by a board-certificated physician.
  • Occurrence of stroke within three months.
  • Upper limb muscle strength ≤ 4 points according to the Medical Research Council Manual Muscle Testing scale.
  • No previous history of stroke, epilepsy, dementia, Parkinson's disease, or other neurodegenerative diseases.
  • Patients could maintain sitting posture for more than 15 minutes on a chair.
  • 18 years of age or older.

Exclusion criteria

Exclusion Criteria:

  • History of recurrent stroke, traumatic brain injuries, brain tumors, spinal cord injury, Parkinson's disease or other musculoskeletal system diseases that may affect evaluation and treatment.
  • Contraindications to focused ultrasound, including pregnancy, cardiac pacemaker or implantable medical device, abnormal connective tissue diseases, coagulopathy (PLT\<100,000/μL, PT>14 seconds, APTT>36 seconds, INR>1.3), implants near or in the brain, or those deemed Unsuitable for this treatment by the physician.
  • Unable to cooperate with treatment or functional assessment due to impaired consciousness or aphasia; inability to informed consent.
  • Patient with cranial bone factor causing the inability of tFUS penetration.
  • Patient under anticoagulants with coagulopathy (PLT\<100,000/μL, PT>14 seconds, APTT>36 seconds, INR>1.3)
  • Patients who are not suitable for undergoing CT imaging examination;
  • Major physical illnesses and neurological disorders (such as epilepsy, brain surgery, etc.)
  • Patients with metallic implants in their bodies;
  • Patients taking tricyclic antidepressants, analgesics, or using antiepileptic drugs
  • Individuals experiencing sleep disorders during tFUS treatment;
  • Individuals with history of alcoholism
  • Patients with severe or uncontrollable intracranial pressure;
  • Patients requiring anticoagulants;
  • Any intracranial space-occupying lesions;
  • Significant calcification of intracranial vessels based on pre-treatment CT imaging;
  • Subjects with lesions/wounds on the scalp in the target region.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment with tFUS

    Treatment with tFUS

    Device: NaviFUS® Neuronavigation-guided focused ultrasound system

  • Sham comparator
    Control

    No ultrasound energy, only the background music will be played.

    Device: NaviFUS® Neuronavigation-guided focused ultrasound system

Interventions

  • DeviceNaviFUS® Neuronavigation-guided focused ultrasound system

    The treatment protocol consists of once daily treatment for consecutive five tFUS sessions.

  • DeviceNaviFUS® Neuronavigation-guided focused ultrasound system

    No ultrasound energy will be delivered (Mechanical Index, MI = 0); only the background music will be played (During each treatment session, the background music will be presented in the same way as in the experimental group during the operation of the focused ultrasound system). All other stimulation settings and procedures will be identical to those used in the experimental group

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-related Adverse Events

    Includes rate of minor (scalp pain, headache, short-term dizziness, nausea, vomiting, short-term weakness, short-term numbness) and severe adverse events (seizure, persistent new onset weakness, documented new intracranial hemorrhage or infarction, death)

    Time frame: Before treatment and on the first day (equal to day 6), first week (equal to day 12), fourth week (equal to day 33), and twelfth week (equal to day 89) after completing consecutive five tFUS sessions.

  2. Cortical excitability

    The amplitude and latency of maximal MEP, rMT in bilateral primary motor cortex will be assessed.

    Time frame: Before treatment and on the first day (equal to day 6), first week (equal to day 12), fourth week (equal to day 33), and twelfth week (equal to day 89) after completing consecutive five tFUS sessions.

Secondary outcomes

  1. Fugl-Meyer Assessment-Upper Extremity

    The Fugl-Meyer Assessment for upper extremity is a standardized tool used to assess motor recovery after stroke. It consists of four items: shoulder/elbow/forearm, wrist, hand, and coordination. Each item is scored individually, with scores ranging from 0 to 2 depending on the quality of the movement. The total score ranges from 0 to 66, with higher scores indicating better motor function and recovery.

    Time frame: Before treatment and on the first day (equal to day 6), first week (equal to day 12), fourth week (equal to day 33), and twelfth week (equal to day 89) after completing consecutive five tFUS sessions.

  2. Medical Research Council score

    The Medical Research Council (MRC) score is a simple and widely used scale to assess muscle strength. It rates muscle strength on a scale from 0 to 5, with 0 being no muscle contraction and 5 being normal muscle strength.

    Time frame: Before treatment and on the first day (equal to day 6), first week (equal to day 12), fourth week (equal to day 33), and twelfth week (equal to day 89) after completing consecutive five tFUS sessions.

  3. National Institutes of Health Stroke Scale (NIHSS)

    The National Institutes of Health Stroke Scale (NIHSS) is a standardized tool used to assess the severity of a stroke and its effects on patients. It evaluates various neurological functions, such as consciousness, movement, sensation, and language, assigning scores ranging from 0 to 42, with higher scores indicating more severe stroke symptoms.

    Time frame: Before treatment and on the first day (equal to day 6), first week (equal to day 12), fourth week (equal to day 33), and twelfth week (equal to day 89) after completing consecutive five tFUS sessions.

  4. Barthel Index

    The Barthel Index is a measure of a person's ability to perform activities of daily living. It assesses functions such as feeding, bathing, grooming, dressing, bowel and bladder control, toileting, transfers, mobility, and stairs. The score ranges from 0 to 100, with higher scores indicating greater independence.

    Time frame: Before treatment and on the first day (equal to day 6), first week (equal to day 12), fourth week (equal to day 33), and twelfth week (equal to day 89) after completing consecutive five tFUS sessions.

  5. Modified Rankin Scale

    The Modified Rankin Scale is a widely used tool to assess a patient's level of disability after a stroke or other neurological disorders. It measures the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death).

    Time frame: Before treatment and on the first day (equal to day 6), first week (equal to day 12), fourth week (equal to day 33), and twelfth week (equal to day 89) after completing consecutive five tFUS sessions.

  6. Functional brain activities

    Functional brain activities were detected by fNIRS (NIRSport2 NIRx Medical Technologies LLC, Glen Head, NY, USA). The subjects were requested to perform functional task (unilateral hand grasping), and brain activities was recorded by fNIRS in the following brain regions: bilateral premotor cortices, supplementary motor area, M1 and primary somatosensory cortices. The ΔHbO2 signal will be analyzed using the HOMER2 fNIRS analysis software.

    Time frame: Before treatment and on the first day (equal to day 6), first week (equal to day 12), fourth week (equal to day 33), and twelfth week (equal to day 89) after completing consecutive five tFUS sessions.

07

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital
    Taipei, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06391086
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Apr 30, 2024
Start date
Aug 1, 2024
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Meng Ting Lin, M.D.
Contact
b96401093@ntu.edu.tw
+886-2312-3456 ext. 67048
Ming Yen Hsiao, M.D.
Contact
myferrant@gmail.com
+886-2312-3456 ext. 67651
Meng Ting Lin, M.D.
principal investigator · National Taiwan University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion